par Soubhye, Jalal 
;Aldib, Iyas ;Prévost, Martine ;Elfving, Betina;Gelbcke, Michel ;Podrecca, Manuel;Conotte, Raphaël;Colet, Jean-Marie ;Furtmüller, Paul G;Delporte, Cédric ;Rousseau, Alexandre ;Vanhaeverbeek, Michel ;Neve, Jean ;Obinger, Christian;Zouaoui Boudjeltia, Karim ;Van Antwerpen, Pierre ;Dufrasne, François
Référence Journal of Pharmacy and Pharmacology, 66, 8, page (1122-1132)
Publication Publié, 2014-03
;Aldib, Iyas ;Prévost, Martine ;Elfving, Betina;Gelbcke, Michel ;Podrecca, Manuel;Conotte, Raphaël;Colet, Jean-Marie ;Furtmüller, Paul G;Delporte, Cédric ;Rousseau, Alexandre ;Vanhaeverbeek, Michel ;Neve, Jean ;Obinger, Christian;Zouaoui Boudjeltia, Karim ;Van Antwerpen, Pierre ;Dufrasne, François Référence Journal of Pharmacy and Pharmacology, 66, 8, page (1122-1132)
Publication Publié, 2014-03
Article révisé par les pairs
| Résumé : | Major depressive disorder (MDD) is accompanied with an imbalance in the immune system and cardiovascular impairments, such as atherosclerosis. Several mechanisms have been pointed out to underlie this rather unexpected association, and among them the activity of myeloperoxidase (MPO). The aim of our study was to find compounds that inhibit both MPO and serotonin transporter (SERT) for treating MDD associated with cardiovascular diseases. |
